245 related articles for article (PubMed ID: 31365764)
21. Impact of Intrahepatic Venovenous Shunt on Hepatic Venous Pressure Gradient Measurement.
Ma J; Gong X; Luo J; Gu J; Yan Z; Zhang W; Li C; Zhang Z; Yang M
J Vasc Interv Radiol; 2020 Dec; 31(12):2081-2088. PubMed ID: 33261743
[TBL] [Abstract][Full Text] [Related]
22. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
[TBL] [Abstract][Full Text] [Related]
23. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis.
Kumar A; Maruyama H; Arora A; Sharma P; Anikhindi SA; Bansal N; Kumar M; Ranjan P; Sachdeva M; Khare S
J Med Ultrason (2001); 2022 Jul; 49(3):333-346. PubMed ID: 35876975
[TBL] [Abstract][Full Text] [Related]
25. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
[TBL] [Abstract][Full Text] [Related]
26. The impact of hepatic steatosis on portal hypertension.
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
[TBL] [Abstract][Full Text] [Related]
27. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
[TBL] [Abstract][Full Text] [Related]
28. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation.
Calvaruso V; Dhillon AP; Tsochatzis E; Manousou P; Grillo F; Germani G; Patch D; O'Beirne J; Burroughs AK
J Gastroenterol Hepatol; 2012 Jul; 27(7):1227-32. PubMed ID: 22432427
[TBL] [Abstract][Full Text] [Related]
29. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis.
Rincón D; Lo Iacono O; Tejedor M; Hernando A; Ripoll C; Catalina MV; Salcedo M; Matilla A; Senosiain M; Clemente G; Molinero LM; Albillos A; Bañares R
Scand J Gastroenterol; 2013 Apr; 48(4):487-95. PubMed ID: 22871085
[TBL] [Abstract][Full Text] [Related]
31. Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension.
Qi X; An W; Liu F; Qi R; Wang L; Liu Y; Liu C; Xiang Y; Hui J; Liu Z; Qi X; Liu C; Peng B; Ding H; Yang Y; He X; Hou J; Tian J; Li Z
Radiology; 2019 Feb; 290(2):370-377. PubMed ID: 30457484
[TBL] [Abstract][Full Text] [Related]
32. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
[TBL] [Abstract][Full Text] [Related]
33. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.
Albillos A; Bañares R; González M; Ripoll C; Gonzalez R; Catalina MV; Molinero LM
Am J Gastroenterol; 2007 May; 102(5):1116-26. PubMed ID: 17391317
[TBL] [Abstract][Full Text] [Related]
34. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
[TBL] [Abstract][Full Text] [Related]
35. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease.
Gharib AM; Han MAT; Meissner EG; Kleiner DE; Zhao X; McLaughlin M; Matthews L; Rizvi B; Abd-Elmoniem KZ; Sinkus R; Levy E; Koh C; Myers RP; Subramanian GM; Kottilil S; Heller T; Kovacs JA; Morse CG
Biomed Res Int; 2017; 2017():2067479. PubMed ID: 28480218
[No Abstract] [Full Text] [Related]
36. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
37. Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment?
Procopeţ B; Tantau M; Bureau C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):73-8. PubMed ID: 23539394
[TBL] [Abstract][Full Text] [Related]
38. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
39. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography.
Pérez-Latorre L; Sánchez-Conde M; Rincón D; Miralles P; Aldámiz-Echevarría T; Carrero A; Tejerina F; Díez C; Bellón JM; Bañares R; Berenguer J
Clin Infect Dis; 2014 Mar; 58(5):713-8. PubMed ID: 24265358
[TBL] [Abstract][Full Text] [Related]
40. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension.
Bauer D; Kozbial K; Schwabl P; Chromy D; Simbrunner B; Stättermayer AF; Pinter M; Steindl-Munda P; Trauner M; Ferenci P; Reiberger T; Mandorfer M
Dig Liver Dis; 2022 Sep; 54(9):1222-1229. PubMed ID: 35382974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
